Tuesday, 18 June 2019
Department of Health
Medicinal Products Reimbursement
370. To ask the Minister for Health if there are age restrictions or otherwise for persons wishing to avail of treatment in view of the fact that Spinraza treatment has been approved; if so, the rationale for imposing a barrier to the treatment; and if he will make a statement on the matter. [25090/19]
The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013; therefore, the matter has been referred to the HSE for reply to the Deputy.